{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T13:44:12Z","timestamp":1782222252590,"version":"3.54.5"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T00:00:00Z","timestamp":1688515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T00:00:00Z","timestamp":1688515200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s11883-023-01120-3","type":"journal-article","created":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T06:02:49Z","timestamp":1688536969000},"page":"487-493","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Lipoprotein(a): a Case for Universal Screening in Youth"],"prefix":"10.1007","volume":"25","author":[{"given":"Aparna","family":"Alankar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Preneet C.","family":"Brar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4179-7402","authenticated-orcid":false,"given":"Brenda","family":"Kohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,5]]},"reference":[{"issue":"8","key":"1120_CR1","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1194\/jlr.R067314","volume":"57","author":"K Schmidt","year":"2016","unstructured":"Schmidt K, Noureen A, Kronenberg F, Utermann G. Structure, function, and genetics of lipoprotein (a). J Lipid Res. 2016;57(8):1339\u201359. https:\/\/doi.org\/10.1194\/jlr.R067314.","journal-title":"J Lipid Res."},{"issue":"7","key":"1120_CR2","doi-asserted-by":"publisher","first-page":"4582","DOI":"10.1016\/S0021-9258(18)32663-2","volume":"258","author":"JW Gaubatz","year":"1983","unstructured":"Gaubatz JW, Heideman C, Gotto AM Jr, Morrisett JD, Dahlen GH. Human plasma lipoprotein [a] Structural properties. J Biol Chem. 1983;258(7):4582\u20139.","journal-title":"J Biol Chem."},{"issue":"17","key":"1120_CR3","doi-asserted-by":"publisher","first-page":"3229","DOI":"10.1021\/bi00767a015","volume":"11","author":"C Ehnholm","year":"1972","unstructured":"Ehnholm C, Garoff H, Renkonen O, Simons K. Protein and carbohydrate composition of Lp(a)lipoprotein from human plasma. Biochemistry. 1972;11(17):3229\u201332. https:\/\/doi.org\/10.1021\/bi00767a015.","journal-title":"Biochemistry"},{"key":"1120_CR4","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.atherosclerosis.2022.04.003","volume":"349","author":"S Coassin","year":"2022","unstructured":"Coassin S, Kronenberg F. Lipoprotein(a) beyond the kringle IV repeat polymorphism: The complexity of genetic variation in the LPA gene. Atherosclerosis. 2022;349:17\u201335. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2022.04.003.","journal-title":"Atherosclerosis"},{"key":"1120_CR5","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/330132a0","volume":"330","author":"J McLean","year":"1987","unstructured":"McLean J, Tomlinson J, Kuang WJ, et al. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature. 1987;330:132\u20137. https:\/\/doi.org\/10.1038\/330132a0.","journal-title":"Nature"},{"issue":"1","key":"1120_CR6","doi-asserted-by":"publisher","first-page":"76","DOI":"10.5935\/abc.20140101","volume":"103","author":"RC Maranh\u00e3o","year":"2014","unstructured":"Maranh\u00e3o RC, Carvalho PO, Strunz CC, Pileggi F. Lipoprotein (a): Structure, pathophysiology and clinical implications. Arq Bras Cardiol. 2014;103(1):76\u201384. https:\/\/doi.org\/10.5935\/abc.20140101.","journal-title":"Arq Bras Cardiol."},{"issue":"1","key":"1120_CR7","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/0021-9150(96)05844-3","volume":"125","author":"HG Kraft","year":"1996","unstructured":"Kraft HG, Lingenhel A, Bader G, et al. The relative electrophoretic mobility of apo(a) isoforms depends on the gel system: Proposal of a nomenclature for apo(a) phenotypes. Atherosclerosis. 1996;125(1):53\u201361.","journal-title":"Atherosclerosis"},{"key":"1120_CR8","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1007\/BF00220066","volume":"90","author":"HG Kraft","year":"1992","unstructured":"Kraft HG, K\u00f6chl S, Menzel HJ, et al. The apolipoprotein (a) gene: A transcribed hypervariable locus controlling plasma lipoprotein (a) concentration. Hum Genet. 1992;90:220\u201330. https:\/\/doi.org\/10.1007\/BF00220066.","journal-title":"Hum Genet"},{"issue":"Suppl 1","key":"1120_CR9","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s11789-017-0084-1","volume":"12","author":"E Ors\u00f3","year":"2017","unstructured":"Ors\u00f3 E, Schmitz G. Lipoprotein(a) and its role in inflammation, atherosclerosis and malignancies. Clin Res Cardiol Suppl. 2017;12(Suppl 1):31\u20137. https:\/\/doi.org\/10.1007\/s11789-017-0084-1.","journal-title":"Clin Res Cardiol Suppl."},{"issue":"11","key":"1120_CR10","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1194\/jlr.R071233","volume":"57","author":"BG Nordestgaard","year":"2016","unstructured":"Nordestgaard BG, Langsted A. Lipoprotein (a) as a cause of cardiovascular disease: Insights from epidemiology, genetics, and biology. J Lipid Res. 2016;57(11):1953\u201375. https:\/\/doi.org\/10.1194\/jlr.R071233.","journal-title":"J Lipid Res."},{"key":"1120_CR11","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1042\/BJ20080744","volume":"418","author":"L Liu","year":"2009","unstructured":"Liu L, Craig AW, Meldrum HD, Marcovina SM, Elliott BE, Koschinsky ML. Apolipoprotein(a) stimulates vascular endothelial cell growth and migration and signals through integrin \u03b1V\u03b23. Biochem J. 2009;418:325\u201336. https:\/\/doi.org\/10.1042\/BJ20080744.","journal-title":"Biochem J."},{"key":"1120_CR12","doi-asserted-by":"publisher","first-page":"30503","DOI":"10.1074\/jbc.M802648200","volume":"283","author":"T Cho","year":"2008","unstructured":"Cho T, Jung Y, Koschinsky ML. Apolipoprotein(a), through its strong lysine-binding site in KIV10, mediates increased endothelial cell contraction and permeability via a Rho\/Rho kinase\/MYPT1-dependent pathway. J Biol Chem. 2008;283:30503\u201312. https:\/\/doi.org\/10.1074\/jbc.M802648200.","journal-title":"J Biol Chem."},{"key":"1120_CR13","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1016\/j.biocel.2013.05.021","volume":"45","author":"K Riches","year":"2013","unstructured":"Riches K, Franklin L, Maqbool A, Peckham M, Adams M, Bond J, et al. Apolipoprotein(a) acts as a chemorepellent to human vascular smooth muscle cells via integrin \u03b1V\u03b23 and RhoA\/ROCK-mediated mechanisms. Int J Biochem Cell Biol. 2013;45:1776\u201383. https:\/\/doi.org\/10.1016\/j.biocel.2013.05.021.","journal-title":"Int J Biochem Cell Biol."},{"key":"1120_CR14","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1007\/s00059-006-2714-0","volume":"31","author":"R Leischik","year":"2006","unstructured":"Leischik R, Dworrak B. Lipoprotein(a): Bedeutung f\u00fcr das fibrinolytische System und thromboembolische Komplikationen. Herz. 2006;31:144\u201352. https:\/\/doi.org\/10.1007\/s00059-006-2714-0.","journal-title":"Herz"},{"key":"1120_CR15","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1002\/path.4133","volume":"229","author":"A Mantovani","year":"2013","unstructured":"Mantovani A, Biswas SK, Galdiero MR, Sica A, Locati M. Macrophage plasticity and polarization in tissue repair and remodeling. J Pathol. 2013;229:176\u201385. https:\/\/doi.org\/10.1002\/path.4133.","journal-title":"J Pathol."},{"key":"1120_CR16","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1159\/000151818","volume":"13","author":"K Berg","year":"1963","unstructured":"Berg K, Mohr J. Genetics of the Lp system. Hum Hered. 1963;13:349\u201360. https:\/\/doi.org\/10.1159\/000151818.","journal-title":"Hum Hered."},{"issue":"2","key":"1120_CR17","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/0005-2795(71)90223-6","volume":"236","author":"C Ehnholm","year":"1971","unstructured":"Ehnholm C, Garoff H, Simons K, Aro H. Purification and quantitation of the human plasma lipoprotein carrying the Lp(a) antigen. Biochim Biophys Acta. 1971;236(2):431\u20139. https:\/\/doi.org\/10.1016\/0005-2795(71)90223-6.","journal-title":"Biochim Biophys Acta."},{"issue":"4","key":"1120_CR18","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1159\/000143403","volume":"66","author":"DC Crawford","year":"2008","unstructured":"Crawford DC, Peng Z, Cheng JF, Boffelli D, Ahearn M, Nguyen D, et al. LPA and PLG sequence variation and kringle IV-2 copy number in two populations. Hum Hered. 2008;66(4):199\u2013209. https:\/\/doi.org\/10.1159\/000143403.","journal-title":"Hum Hered."},{"key":"1120_CR19","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.atherosclerosis.2008.01.002","volume":"201","author":"J Rubin","year":"2008","unstructured":"Rubin J, Kim HJ, Pearson TA, Holleran S, Berglund L, Ramakrishnan R. The apolipoprotein(a) gene: linkage disequilibria at three loci differs in African Americans and Caucasians. Atherosclerosis. 2008;201:138\u201347. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2008.01.002.","journal-title":"Atherosclerosis"},{"key":"1120_CR20","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1136\/jmg.2006.042119","volume":"43","author":"JP Chretien","year":"2006","unstructured":"Chretien JP, Coresh J, Berthier-Schaad Y, Kao WH, Fink NE, Klag MJ, et al. Three single-nucleotide polymorphisms in LPA account for most of the increase in lipoprotein(a) level elevation in African Americans compared with European Americans. J Med Genet. 2006;43:917\u201323. https:\/\/doi.org\/10.1136\/jmg.2006.042119.","journal-title":"J Med Genet."},{"key":"1120_CR21","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.atherosclerosis.2022.04.008","volume":"349","author":"F Kronenberg","year":"2022","unstructured":"Kronenberg F. Lipoprotein(a) measurement issues: Are we making a mountain out of a molehill? Atherosclerosis. 2022;349:123\u201335. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2022.04.008.","journal-title":"Atherosclerosis"},{"issue":"2","key":"1120_CR22","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1093\/clinchem\/41.2.246","volume":"41","author":"SM Marcovina","year":"1995","unstructured":"Marcovina SM, Albers JJ, Gabel B, Koschinsky ML, Gaur VP. Effect of the number of apolipoprotein(a) kringle 4 domains on immunochemical measurements of lipoprotein(a). Clin Chem. 1995;41(2):246\u201355.","journal-title":"Clin Chem."},{"issue":"2","key":"1120_CR23","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1172\/JCI113093","volume":"80","author":"G Utermann","year":"1987","unstructured":"Utermann G, Menzel HJ, Kraft HG, Duba HC, Kemmler HG, Seitz C. Lp(a) glycoprotein phenotypes. Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma. J Clin Invest. 1987;80(2):458\u201365. https:\/\/doi.org\/10.1172\/JCI113093.","journal-title":"J Clin Invest."},{"issue":"4","key":"1120_CR24","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1194\/jlr.R061648","volume":"57","author":"SM Marcovina","year":"2016","unstructured":"Marcovina SM, Albers JJ. Lipoprotein (a) measurements for clinical application. J Lipid Res. 2016;57(4):526\u201337. https:\/\/doi.org\/10.1194\/jlr.R061648.","journal-title":"J Lipid Res."},{"issue":"3","key":"1120_CR25","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.jacl.2019.04.010","volume":"13","author":"DP Wilson","year":"2019","unstructured":"Wilson DP, Jacobson TA, Jones PH, Koschinsky ML, McNeal CJ, Nordestgaard BG, et al. Use of lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association. J Clin Lipidol. 2019;13(3):374\u201392. https:\/\/doi.org\/10.1016\/j.jacl.2019.04.010. Epub 2019 May 17. Erratum in: J Clin Lipidol. 2022 Aug 26.","journal-title":"J Clin Lipidol."},{"issue":"1","key":"1120_CR26","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3390\/biom12010026","volume":"12","author":"S Ugov\u0161ek","year":"2021","unstructured":"Ugov\u0161ek S, \u0160ebe\u0161tjen M. Lipoprotein(a)-The crossroads of atherosclerosis, atherothrombosis and inflammation. Biomolecules. 2021;12(1):26. https:\/\/doi.org\/10.3390\/biom12010026.","journal-title":"Biomolecules"},{"issue":"4","key":"1120_CR27","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1001\/jama.2009.1063","volume":"302","author":"S Erqou","year":"2009","unstructured":"Emerging Risk Factors Collaboration, Erqou S, Kaptoge S, Perry PL, Di Angelantonio E, Thompson A, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA. 2009;302(4):412\u201323. https:\/\/doi.org\/10.1001\/jama.2009.1063.","journal-title":"JAMA"},{"issue":"1","key":"1120_CR28","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1093\/clinchem\/hvaa247","volume":"67","author":"PR Kamstrup","year":"2021","unstructured":"Kamstrup PR. Lipoprotein(a) and cardiovascular disease. Clin Chem. 2021;67(1):154\u201366. https:\/\/doi.org\/10.1093\/clinchem\/hvaa247.","journal-title":"Clin Chem."},{"issue":"3","key":"1120_CR29","doi-asserted-by":"publisher","first-page":"151","DOI":"10.2459\/JCM.0000000000001077","volume":"22","author":"A Cesaro","year":"2021","unstructured":"Cesaro A, Schiavo A, Moscarella E, Coletta S, Conte M, Gragnano F, et al. Lipoprotein(a): A genetic marker for cardiovascular disease and target for emerging therapies. J Cardiovasc Med (Hagerstown). 2021;22(3):151\u201361. https:\/\/doi.org\/10.2459\/JCM.0000000000001077.","journal-title":"J Cardiovasc Med (Hagerstown)."},{"issue":"6","key":"1120_CR30","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1007\/s10557-019-06906-9","volume":"33","author":"MF Wu","year":"2019","unstructured":"Wu MF, Xu KZ, Guo YG, Yu J, Wu Y, Lin LM. Lipoprotein(a) and atherosclerotic cardiovascular disease: Current understanding and future perspectives. Cardiovasc Drugs Ther. 2019;33(6):739\u201348. https:\/\/doi.org\/10.1007\/s10557-019-06906-9.","journal-title":"Cardiovasc Drugs Ther."},{"issue":"1","key":"1120_CR31","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s12291-015-0483-3","volume":"31","author":"A Manocha","year":"2016","unstructured":"Manocha A, Srivastava LM. Lipoprotein (a): A unique independent risk factor for coronary artery disease. Indian. J Clin Biochem. 2016;31(1):13\u201320. https:\/\/doi.org\/10.1007\/s12291-015-0483-3.","journal-title":"J Clin Biochem."},{"issue":"8","key":"1120_CR32","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1161\/01.atv.14.8.1337","volume":"14","author":"GA Keesler","year":"1994","unstructured":"Keesler GA, Li Y, Skiba PJ, Fless GM, Tabas I. Macrophage foam cell lipoprotein(a)\/apoprotein(a) receptor. Cell-surface localization, dependence of induction on new protein synthesis, and ligand specificity. Arterioscler Thromb. 1994;14(8):1337\u201345. https:\/\/doi.org\/10.1161\/01.atv.14.8.1337.","journal-title":"Arterioscler Thromb."},{"issue":"5","key":"1120_CR33","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.jacc.2013.09.038","volume":"63","author":"PR Kamstrup","year":"2014","unstructured":"Kamstrup PR, Tybj\u00e6rg-Hansen A, Nordestgaard BG. Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population. J Am Coll Cardiol. 2014;63(5):470\u20137. https:\/\/doi.org\/10.1016\/j.jacc.2013.09.038.","journal-title":"J Am Coll Cardiol."},{"key":"1120_CR34","unstructured":"McNeal CJ, Peterson AL. Feingold KR, Anawalt B, Boyce A, et al., editors. Lipoprotein (a) in youth. [Updated 2020 Feb 9]. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK395570\/. Accessed 21 Nov 2022."},{"issue":"23","key":"1120_CR35","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","volume":"31","author":"BG Nordestgaard","year":"2010","unstructured":"Nordestgaard BG, Chapman MJ, Ray K, Bor\u00e9n J, Andreotti F, Watts GF, et al. European Atherosclerosis Society Consensus Panel. Lipoprotein(a) as a cardiovascular risk factor: Current status. Eur Heart J. 2010;31(23):2844\u201353. https:\/\/doi.org\/10.1093\/eurheartj\/ehq386.","journal-title":"Eur Heart J."},{"key":"1120_CR36","unstructured":"National Heart, Lung, and Blood Institute. (2012). Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents. https:\/\/www.nhlbi.nih.gov\/files\/docs\/guidelines\/peds_guidelines_full.pdf. Accessed 21 Nov 2022."},{"key":"1120_CR37","unstructured":"Universal cholesterol screening referral guidelines. 2022. Children\u2019s National. https:\/\/childrensnational.org\/healthcare-providers\/refer-a-patient\/referral-guidelines\/universal-cholesterol-screening-guidelines. Accessed 21 Nov 2022."},{"key":"1120_CR38","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, et al. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111\u201388.","journal-title":"Eur Heart J."},{"key":"1120_CR39","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1097\/MED.0000000000000624","volume":"28","author":"DP Wilson","year":"2021","unstructured":"Wilson DP, Koschinsky ML, Moriarty PM. Expert position statements: Comparison of recommendations for the care of adults and youth with elevated lipoprotein (a). Curr Opin Endocrinol Diabetes Obes. 2021;28:159\u201373. This comprehensive review provides an analysis of our current understanding of Lp(a) and recommendations for clinical practice.","journal-title":"Curr Opin Endocrinol Diabetes Obes."},{"key":"1120_CR40","doi-asserted-by":"publisher","first-page":"e603","DOI":"10.1161\/CIR.0000000000000618","volume":"139","author":"SD De Ferranti","year":"2019","unstructured":"De Ferranti SD, Steinberger J, Ameduri R, et al. Cardiovascular risk reduction in high-risk pediatric patients: A scientific statement from the American Heart Association. Circulation. 2019;139:e603\u201334.","journal-title":"Circulation"},{"issue":"5 Suppl","key":"1120_CR41","doi-asserted-by":"publisher","first-page":"S57","DOI":"10.1016\/j.jacl.2015.07.006","volume":"9","author":"CJ McNeal","year":"2015","unstructured":"McNeal CJ. Lipoprotein(a): Its relevance to the pediatric population. J Clin Lipidol. 2015;9(5 Suppl):S57\u201366. https:\/\/doi.org\/10.1016\/j.jacl.2015.07.006.","journal-title":"J Clin Lipidol."},{"issue":"9","key":"1120_CR42","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.jacc.2018.12.037","volume":"73","author":"KL Ellis","year":"2019","unstructured":"Ellis KL, P\u00e9rez de Isla L, Alonso R, Fuentes F, Watts GF, Mata P. Value of measuring lipoprotein(a) during cascade testing for familial hypercholesterolemia. J Am Coll Cardiol. 2019;73(9):1029\u201339. https:\/\/doi.org\/10.1016\/j.jacc.2018.12.037.","journal-title":"J Am Coll Cardiol."},{"issue":"1","key":"1120_CR43","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1161\/ATVBAHA.119.312951","volume":"40","author":"CM Madsen","year":"2020","unstructured":"Madsen CM, Kamstrup PR, Langsted A, Varbo A, Nordestgaard BG. Lipoprotein(a)-lowering by 50\u00a0mg\/dL (105\u00a0nmol\/L) may be needed to reduce cardiovascular disease 20% in secondary prevention: A population-based study. Arterioscler Thromb Vasc Biol. 2020;40(1):255\u201366. https:\/\/doi.org\/10.1161\/ATVBAHA.119.312951.","journal-title":"Arterioscler Thromb Vasc Biol."},{"issue":"5","key":"1120_CR44","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.jacc.2021.04.103","volume":"78","author":"RS Rosenson","year":"2021","unstructured":"Rosenson RS, Goonewardena SN. The residual risk Odyssey: From LDL to Lp(a). J Am Coll Cardiol. 2021;78(5):434\u20136. https:\/\/doi.org\/10.1016\/j.jacc.2021.04.103.","journal-title":"J Am Coll Cardiol."},{"issue":"11","key":"1120_CR45","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1007\/s11883-022-01060-4","volume":"24","author":"NS Nurmohamed","year":"2022","unstructured":"Nurmohamed NS, Kraaijenhof JM, Stroes ESG. Lp(a): A new pathway to target? Curr Atheroscler Rep. 2022;24(11):831\u20138. https:\/\/doi.org\/10.1007\/s11883-022-01060-4.","journal-title":"Curr Atheroscler Rep."},{"issue":"2275\u201384","key":"1120_CR46","first-page":"28","volume":"41","author":"S Tsimikas","year":"2020","unstructured":"Tsimikas S, Gordts PLSM, Nora C, Yeang C, Witztum JL. Statin therapy increases lipoprotein(a) levels. Eur Heart J. 2020;41(2275\u201384):28.","journal-title":"Eur Heart J."},{"key":"1120_CR47","doi-asserted-by":"crossref","unstructured":"de Boer LM, Oorthuys AOJ, Wiegman A, Langendam MW, Kroon J, Spijker R, et al. Statin therapy and lipoprotein(a) levels: A systematic review and meta-analysis. Eur J Prev Cardiol. 2021;zwab171.","DOI":"10.1016\/j.atherosclerosis.2022.06.202"},{"issue":"17887","key":"1120_CR48","first-page":"30","volume":"8","author":"A Sahebkar","year":"2018","unstructured":"Sahebkar A, Simental-Mend\u00eda LE, Pirro M, Banach M, Watts GF, Sirtori C, et al. Impact of ezetimibe on plasma lipoprotein(a) concentrations as monotherapy or in combination with statins: a systematic review and meta-analysis of randomized controlled trials. Sci Rep. 2018;8(17887):30.","journal-title":"Sci Rep."},{"key":"1120_CR49","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s40265-018-0870-1","volume":"78","author":"K Awad","year":"2018","unstructured":"Awad K, Mikhailidis DP, Katsiki N, Muntner P, Banach M, Group on behalf of L and BPM-AC (LBPMC). Effect of ezetimibe monotherapy on plasma lipoprotein(a) concentrations in patients with primary hypercholesterolemia: A systematic review and meta-analysis of randomized controlled trials. Drugs. 2018;78:453\u201362.","journal-title":"Drugs"},{"issue":"1564\u201375","key":"1120_CR50","first-page":"34","volume":"77","author":"NS Nurmohamed","year":"2021","unstructured":"Nurmohamed NS, Navar AM, Kastelein JJP. New and emerging therapies for reduction of LDL-cholesterol and apolipoprotein B: JACC Focus Seminar 1\/4. J Am Coll Cardiol Am College Cardiol Found. 2021;77(1564\u201375):34.","journal-title":"J Am Coll Cardiol Am College Cardiol Found."},{"key":"1120_CR51","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.jacl.2021.05.002","volume":"15","author":"J Rubino","year":"2021","unstructured":"Rubino J, MacDougall DE, Sterling LR, Kelly SE, McKenney JM, Lalwani ND. Lipid lowering with bempedoic acid added to a proprotein convertase subtilisin\/kexin type 9 inhibitor therapy: A randomized, controlled trial. J Clin Lipidol. 2021;15:593\u2013601.","journal-title":"J Clin Lipidol."},{"key":"1120_CR52","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med Mass Med Soc. 2018;379:2097\u2013107.","journal-title":"N Engl J Med Mass Med Soc."},{"issue":"2","key":"1120_CR53","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jacc.2019.10.057","volume":"75","author":"VA Bittner","year":"2020","unstructured":"Bittner VA, Szarek M, Aylward PE, Bhatt DL, Diaz R, Edelberg JM, et al. ODYSSEY OUTCOMES Committees and Investigators. Effect of alirocumab on lipoprotein(a) and cardiovascular risk after acute coronary syndrome. J Am Coll Cardiol. 2020;75(2):133\u201344. https:\/\/doi.org\/10.1016\/j.jacc.2019.10.057.","journal-title":"J Am Coll Cardiol."},{"key":"1120_CR54","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med Massachusetts Med Soc. 2017;376:1713\u201322.","journal-title":"N Engl J Med Massachusetts Med Soc."},{"issue":"16","key":"1120_CR55","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","volume":"382","author":"FJ Raal","year":"2020","unstructured":"Raal FJ, Kallend D, Ray KK, Turner T, Koenig W, Wright RS, et al. Kastelein JJP; ORION-9 Investigators. Inclisiran for the treatment of heterozygous familial hypercholesterolemia. N Engl J Med. 2020;382(16):1520\u201330. https:\/\/doi.org\/10.1056\/NEJMoa1913805.","journal-title":"N Engl J Med."},{"issue":"8","key":"1120_CR56","doi-asserted-by":"publisher","first-page":"679","DOI":"10.5551\/jat.RV17033","volume":"26","author":"H Makino","year":"2019","unstructured":"Makino H, Koezuka R, Tamanaha T, Ogura M, Matsuki K, Hosoda K, et al. Familial hypercholesterolemia and lipoprotein apheresis. J Atheroscler Thromb. 2019;26(8):679\u201387. https:\/\/doi.org\/10.5551\/jat.RV17033.","journal-title":"J Atheroscler Thromb."},{"key":"1120_CR57","first-page":"229","volume":"6","author":"BR Jaeger","year":"2009","unstructured":"Jaeger BR, Richter Y, Nagel D, Heigl F, Vogt A, Roeseler E, et al. Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events. Nat Clin Pract Cardiovasc Med. 2009;6:229\u201339.","journal-title":"Nat Clin Pract Cardiovasc Med."},{"issue":"6","key":"1120_CR58","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/j.jacl.2019.09.010","volume":"13","author":"PM Moriarty","year":"2019","unstructured":"Moriarty PM, Gray JV, Gorby LK. Lipoprotein apheresis for lipoprotein(a) and cardiovascular disease. J Clin Lipidol. 2019;13(6):894\u2013900. https:\/\/doi.org\/10.1016\/j.jacl.2019.09.010.","journal-title":"J Clin Lipidol."},{"issue":"7","key":"1120_CR59","doi-asserted-by":"publisher","first-page":"e003294","DOI":"10.1161\/JAHA.116.003294","volume":"5","author":"A Wang","year":"2016","unstructured":"Wang A, Richhariya A, Gandra SR, Calimlim B, Kim L, Quek RG, et al. Systematic review of low-density lipoprotein cholesterol apheresis for the treatment of familial hypercholesterolemia. J Am Heart Assoc. 2016;5(7):e003294. https:\/\/doi.org\/10.1161\/JAHA.116.003294.","journal-title":"J Am Heart Assoc."},{"issue":"9","key":"1120_CR60","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.3390\/biomedicines9091271","volume":"9","author":"VA Korneva","year":"2021","unstructured":"Korneva VA, Kuznetsova TY, Julius U. Modern approaches to lower lipoprotein(a) concentrations and consequences for cardiovascular diseases. Biomedicines. 2021;9(9):1271. https:\/\/doi.org\/10.3390\/biomedicines9091271.","journal-title":"Biomedicines"},{"key":"1120_CR61","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1016\/S0140-6736(16)31009-1","volume":"388","author":"NJ Viney","year":"2016","unstructured":"Viney NJ, van Capelleveen JC, Geary RS, Xia S, Tami JA, Yu RZ, et al. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): Two randomised, double blind, placebo-controlled, dose-ranging trials. Lancet Elsevier Ltd. 2016;388:2239\u201353.","journal-title":"Lancet Elsevier Ltd."},{"key":"1120_CR62","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1056\/NEJMoa1905239","volume":"382","author":"S Tsimikas","year":"2020","unstructured":". Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, Tardif J-C, Baum SJ, Steinhagen-Thiessen E, et al. Lipoprotein(a) reduction in persons with cardiovascular disease. N Engl J Med Massachusetts Med Soc. 2020;382:244\u201355. This study presents a dose-dependent reduction in lipoprotein (a) levels after administration of the antisense oligonucleotide AKCEA-APO(a) \u2013L RX in patients with established cardiovascular disease. Future studies defining the role of reductions in Lp(a) levels in the prevention of cardiovascular disease will help to further elucidate the role of high Lp(a) in ASCVD.","journal-title":"N Engl J Med Massachusetts Med Soc."},{"issue":"3","key":"1120_CR63","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/d41573-020-00028-w","volume":"19","author":"E Dolgin","year":"2020","unstructured":"Dolgin E. Lp(a)-lowering drugs bolster cardiovascular pipeline. Nat Rev Drug Discov. 2020;19(3):154\u20135. https:\/\/doi.org\/10.1038\/d41573-020-00028-w.","journal-title":"Nat Rev Drug Discov."},{"key":"1120_CR64","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/s41591-021-01634-w","volume":"28","author":"MJ Koren","year":"2022","unstructured":". Koren MJ, Moriarty PM, Baum SJ, Neutel J, Hernandez-Illas M, Weintraub HS, et al. Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a). Nat Med. 2022;28:96\u2013103. This study presents results of an early phase I trial of a novel siRNA targeting lipoprotein(a).","journal-title":"Nat Med."},{"issue":"17","key":"1120_CR65","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1001\/jama.2022.5050","volume":"327","author":"SE Nissen","year":"2022","unstructured":"Nissen SE, Wolski K, Balog C, Swerdlow DI, Scrimgeour AC, Rambaran C, et al. Single ascending dose study of a short interfering RNA targeting lipoprotein(a) production in individuals with elevated plasma lipoprotein(a) levels. JAMA. 2022;327(17):1679\u201387.","journal-title":"JAMA"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-023-01120-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11883-023-01120-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-023-01120-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T09:24:16Z","timestamp":1691573056000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11883-023-01120-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,5]]},"references-count":65,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["1120"],"URL":"https:\/\/doi.org\/10.1007\/s11883-023-01120-3","relation":{},"ISSN":["1523-3804","1534-6242"],"issn-type":[{"value":"1523-3804","type":"print"},{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,5]]},"assertion":[{"value":"14 June 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}